Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease

Journal of Neurochemistry

Volumn 101, Issue 2, 2007, Pages 483-497

  Mela, Flora ^a,b   Marti, Matteo ^b   Dekundy, Andrzej ^c   Danysz, Wojciech ^c   Morari, Michele ^b   Cenci, M Angela ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF FERRARA   (Italy)

^c MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

3 (2 methyl 1,3 thiazol 4 yl)ethynyl pyridine; Dynorphin; Enkephalin.; GABA; L DOPA induced dyskinesia; Metabotropic glutamate receptor 5

Indexed keywords

3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 4 AMINOBUTYRIC ACID; BENSERAZIDE; LEVODOPA; MESSENGER RNA; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; OXIDOPAMINE; PRODYNORPHIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG WITHDRAWAL; DYSKINESIA; HISTOCHEMISTRY; IN SITU HYBRIDIZATION; NEUROCHEMISTRY; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RECEPTOR INTRINSIC ACTIVITY; TASK PERFORMANCE; THERAPY EFFECT; TISSUE SECTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ANTIPARKINSON AGENTS; BRAIN; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; EXCITATORY AMINO ACID ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; LEVODOPA; MICRODIALYSIS; NEURAL INHIBITION; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SUBSTANTIA NIGRA; SYNAPTIC TRANSMISSION;

ANIMALIA; RATTUS;

EID: 34047186385     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.04456.x     Document Type: Article

References (85)

1. Adams A. C., Layer R. T., McCabe R. T. and Keefe K. A. (2000) Effects of conantokins on L-3,4-dihydroxyphenylalanine-induced behavior and immediate early gene expression. Eur. J. Pharmacol. 404, 303-313.
2. Albin R. L., Young A. B. and Penney J. B. (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366-375.
3. Anderson J. J., Bradbury M. J., Giracello D. R., Chapman D. F., Holz G., Roppe J., King C., Cosford N. D. and Varney M. A. (2003) In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine. Eur. J. Pharmacol. 18, 35-40.
4. Andersson M., Hilbertson A. and Cenci M. A. (1999) Striatal fosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 6, 461-474.
5. Andersson M., Konradi C. and Cenci M. A. (2001) cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J. Neurosci. 21, 9930-9943.
6. Andersson M., Westin J. E. and Cenci M. A. (2003) Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment. Eur. J. Neurosci. 17, 661-666.
7. Aubert I., Guigoni C., Hakansson K. et al. (2005) Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 57, 17-26.
8. Bezard E., Brotchie J. M. and Gross C. E. (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. 2, 577-588.
9. Blanchet P. J., Metman L. V. and Chase T. N. (2003) Renaissance of amantadine in the treatment of Parkinson's disease. Adv. Neurol. 91, 251-257.
10. Breysse N., Baunez C., Spooren W., Gasparini F. and Amalric M. (2002) Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J. Neurosci. 22, 5669-5678.
11. Breysse N., Amalric M. and Salin P. (2003) Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats. J. Neurosci. 23, 8302-8309.
12. Brotchie J. M., Lee J. and Venderova K. (2005) Levodopa-induced dyskinesia in Parkinson's disease. J. Neural. Transm. 112, 359-391.
13. Brown T., de Groote C. and Brotchie J. M. (2002) Recent advances in the treatment of L-DOPA-induced dyskinesia. Drugs 5, 454-468.
14. Busse C. S., Brodkin J., Tattersall D., Anderson J. J., Warren N., Tehrani L., Bristow L. J., Varney M. A. and Cosford N. D. (2004) The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 29, 1971-1979.
15. Calon F., Grondin R., Morissette M., Goulet M., Blanchet P. J., Di Paolo T. and Bedard P. J. (2000) Molecular basis of levodopa-induced dyskinesias. Ann. Neurol. 47, S70-S78.
16. Carta A. R., Tronci E., Pinna A. and Morelli M. (2005) Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment. Eur. J. Neurosci. 21, 1196-1204.
17. Carta M., Lindgren H. S., Lundblad M., Stancampiano R., Fadda F. and Cenci M. A. (2006) Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem. 96, 1718-1727.
18. Cenci M. A. (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci. in press.
19. Cenci M. A. and Lundblad M. (2006) Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J. Neurochem. 99, 381-392.
20. Cenci M. A., Lee C. S. and Bjorklund A. (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10, 2694-2706.
21. Chase T. N. (1998) Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 50, S17-S25.
22. Chase T. N. and Oh J. D. (2000) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 23, S86-S91.
23. Chase T. N., Oh J. D. and Konitsiotis S. (2000) Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J. Neurol. 247(Suppl 2), 1136-1142.
24. Congar P., Leinekugel X., Ben-Ari Y. and Crepel V. (1997) A long-lasting calcium-activated nonselective cationic current is generated by synaptic stimulation or exogenous activation of group I metabotropic glutamate receptors in CA1 pyramidal neurons. J. Neurosci. 17, 5366-5379.
25. Da Prada M., Kettler R., Zurcher G., Schaffner R. and Haefely W. E. (1987) Inhibition of decarboxylase and levels of dopa and 3-o-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Eur. Neurol. 27(Suppl. 1), 9-20.
26. Dekundy A., Pietraszek M., Schaefer D., Cenci M. A. and Danysz W. (2006) Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res. Bull. 69, 318-326.
27. Fahn S. (2000) The spectrum of levodopa-induced dyskinesias. Ann. Neurol. 47, S2-S9.
28. Ferre S., Popoli P., Rimondini R., Reggio R., Kehr J. and Fuxe K. (1999) Adenosine A2A and group I metabotropic glutamate receptors synergistically modulate the binding characteristics of dopamine D2 receptors in the rat striatum. Neuropharmacology 38, 129-140.
29. Fredduzzi S., Moratalla R., Monopoli A., Cuellar B., Xu K., Ongini E., Impagnatiello F., Schwarzschild M. A. and Chen J. F. (2002) Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J. Neurosci. 22, 1054-1062.
30. Ganguly A. and Keefe K. A. (2000) Effects of MK-801 on D1 dopamine receptor-mediated immediate early gene expression in the dopamine-depleted striatum. Brain Res. 871, 156-159.
31. Gerfen C. R. (1992) The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu. Rev. Neurosci. 15, 285-320.
32. Grange S., Holford N. H. and Guentert T. W. (2001) A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats. Pharm. Res. 18, 1174-1184.
33. Gubellini P., Pisani A., Centonze D., Bernardi G. and Calabresi P. (2004) Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases. Prog. Neurobiol. 74, 271-300.
34. Henry B., Duty S., Fox S. H., Crossman A. R. and Brotchie J. M. (2003) Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp. Neurol. 183, 458-468.
35. Hill M. P., McGuire S. G., Crossman A. R. and Brotchie J. M. (2001) The mGlu5 receptor antagonist SIB-1830 reduces L-DOPA-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's Disease. Abstr. Soc. Neurosci. 27, Abs200.217.
36. Jenner P. (2000) Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann. Neurol. 47, S90-S99; discussion S99-S104.
37. Johansson P. A., Andersson M., Andersson K. E. and Cenci M. A. (2001) Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of L-DOPA-induced dyskinesia. Neurobiol. Dis. 8, 220-239.
38. Kearney J. A. and Albin R. L. (1995) Adenosine A2 receptor-mediated modulation of contralateral rotation induced by metabotropic glutamate receptor activation. Eur. J. Pharmacol. 287, 115-120.
39. Keefe K. A. and Gerfen C. R. (1996) D1 dopamine receptor-mediated induction of zif268 and c-fos in the dopamine-depleted striatum: differential regulation and independence from NMDA receptors. J. Comp. Neurol. 367, 165-176.
40. Kerner J. A., Standaert D. G., Penney J. B. Jr, Young A. B. and Landwehrmeyer G. B. (1997) Expression of group one metabotropic glutamate receptor subunit mRNAs in neurochemically identified neurons in the rat neostriatum, neocortex, and hippocampus. Brain Res. Mol. Brain Res. 48, 259-269.
41. Kincaid A. E. and Wilson C. J. (1996) Corticostriatal innervation of the patch and matrix in the rat neostriatum. J. Comp. Neurol. 374, 578-592.
42. Konieczny J., Ossowska K., Wolfarth S. and Pilc A. (1998) LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats. Naunyn Schmiedebergs Arch. Pharmacol. 358, 500-502.
43. Konradi C., Westin J. E., Carta M., Eaton M. E., Kuter K., Dekundy A., Lundblad M. and Cenci M. A. (2004) Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol. Dis. 17, 219-236.
44. Lee C. S., Cenci M. A., Schulzer M. and Bjorklund A. (2000) Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 123 (Pt 7) 1365-1379.
45. Lorenc-Koci E., Wardas J., Wolfarth S. and Pilc A. (2001) (S)-4C3HPG, a mixed group I mGlu receptor antagonist and a group II agonist, administered intrastriatally, counteracts parkinsonian-like muscle rigidity in rats. Brain Res. 903, 177-184.
46. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N. and Cenci M. A. (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15, 120-132.
47. Lundblad M., Vaudano E. and Cenci M. A. (2003) Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J. Neurochem. 84, 1398-1410.
48. Lundblad M., Picconi B., Lindgren H. and Cenci M. A. (2004) A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 16, 110-123.
49. Mao L. and Wang J. Q. (2001) Selective activation of group I metabotropic glutamate receptors upregulates preprodynorphin, substance P, and preproenkephalin mRNA expression in rat dorsal striatum. Synapse 39, 82-94.
50. Mao L. and Wang J. Q. (2002) Glutamate cascade to cAMP response element-binding protein phosphorylation in cultured striatal neurons through calcium-coupled group I metabotropic glutamate receptors. Mol. Pharmacol. 62, 473-484.
51. Mao L. and Wang J. Q. (2003) Metabotropic glutamate receptor 5-regulated Elk-1 phosphorylation and immediate early gene expression in striatal neurons. J. Neurochem. 85, 1006-1017.
52. Marino M. J., Williams D. L., O'Brien J. A. et al. (2003) Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc. Natl Acad. Sci. USA 100, 13 668-13 673.
53. Mark K. A., Soghomonian J. J. and Yamamoto B. K. (2004) High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J. Neurosci. 24, 11 449-11 456.
54. 2 receptors. J. Neurochem. 83, 635-644.
55. Marti M., Paganini F., Stocchi S., Mela F., Beani L., Bianchi C. and Morari M. (2003) Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors. J. Neurochem. 84, 792-802.
56. Marti M., Mela F., Fantin M. et al. (2005) Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J. Neurosci. 25, 9591-9601.
57. McGeorge A. J. and Faull R. L. (1989) The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience 29, 503-537.
58. Meldrum B. S. (1998) The glutamate synapse as a therapeutical target: perspectives for the future. Prog. Brain Res. 116, 441-458.
59. Morari M., O'Connor W. T., Ungerstedt U., Bianchi C. and Fuxe K. (1996) Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat-II. Evidence for striatal N-methyl-D-aspartate receptor regulation of striatonigral GABAergic transmission and motor function. Neuroscience 72, 89-97.
60. Nakanishi S., Nakajima Y., Masu M., Ueda Y., Nakahara K., Watanabe D., Yamaguchi S., Kawabata S. and Okada M. (1998) Glutamate receptors: brain function and signal transduction. Brain Res. Brain Res. Rev. 26, 230-235.
61. Obeso J. A., Olanow C. W. and Nutt J. G. (2000) Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23, S2-S7.
62. Obeso J. A., Rodriguez-Oroz M., Marin C., Alonso F., Zamarbide I., Lanciego J. L. and Rodriguez-Diaz M. (2004) The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 62, S17-S30.
63. Ossowska K., Konieczny J., Wolfarth S., Wieronska J. and Pilc A. (2001) Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology 41, 413-420.
64. Paxinos G. and Watson C. (1997) The rat brain in stereotaxic coordinates. Academic Press, San Diego, CA, USA.
65. Pin J. P. and Duvoisin R. (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34, 1-26.
66. Pintor A., Pezzola A., Reggio R., Quarta D. and Popoli P. (2000) The mGlu5 receptor agonist CHPG stimulates striatal glutamate release: possible involvement of A2A receptors. Neuroreport 11, 3611-3614.
67. Pisani A., Calabresi P., Centonze D. and Bernardi G. (1997) Activation of group III metabotropic glutamate receptors depresses glutamatergic transmission at corticostriatal synapse. Neuropharmacology 36, 845-851.
68. Rascol O., Sabatini U., Brefel C., Fabre N., Rai S., Senard J. M., Celsis P., Viallard G., Montastruc J. L. and Chollet F. (1998) Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. Brain 121 (Pt 3) 527-533.
69. Robelet S., Melon C., Guillet B., Salin P. and Kerkerian-Le Goff L. (2004) Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. Eur. J. Neurosci. 20, 1255-1266.
70. Rouse S. T., Marino M. J., Bradley S. R., Awad H., Wittmann M. and Conn P. J. (2000) Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol. Ther. 88, 427-435.
71. Schallert T. and Tillerson J. L. (2000) Intervention strategies for degeneration of dopamine neurons in parkinsonism: optimizing behavioral assessment of outcome, in Central Nervous System Diseases: Innovative Models of CNS Diseases from Molecule to Therapy (Emerich D. F., Dean R. L. and Sanberg P. R., eds), pp. 131-151. Humana Press, Totowa, NJ, USA.
72. Sgambato-Faure V., Buggia V., Gilbert F., Levesque D., Benabid A. L. and Berger F. (2005) Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats. J. Neuropathol. Exp. Neurol. 64, 936-947.
73. Spooren W. P., Gasparini F., Bergmann R. and Kuhn R. (2000) Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. Eur. J. Pharmacol. 406, 403-410.
74. Standaert D. G., Testa C. M., Young A. B. and Penney J. B. (1994) Organization of N-methyl-D-aspartate glutamate-receptor gene expression in the basal ganglia of the rat. J. Comp. Neurol. 343, 1-16.
75. St-Hilaire M., Landry E., Levesque D. and Rouillard C. (2005) Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism. Neurobiol. Dis. 20, 450-460.
76. Tel B. C., Zeng B. Y., Cannizzaro C., Pearce R. K., Rose S. and Jenner P. (2002) Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience 115, 1047-1058.
77. Testa C. M., Standaert D. G., Young A. B. and Penney J. B. Jr (1994) Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J. Neurosci. 14, 3005-3018.
78. Testa C. M., Standaert D. G., Landwehrmeyer G. B., Penney J. B. Jr and Young A. B. (1995) Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons. J. Comp. Neurol. 354, 241-252.
79. Trugman J. M. and Wooten G. F. (1986) The effects of L-DOPA on regional cerebral glucose utilization in rats with unilateral lesions of the substantia nigra. Brain Res. 379, 264-274.
80. Voulalas P. J., Holtzclaw L., Wolstenholme J., Russell J. T. and Hyman S. E. (2005) Metabotropic glutamate receptors and dopamine receptors cooperate to enhance extracellular signal-regulated kinase phosphorylation in striatal neurons. J. Neurosci. 25, 3763-3773.
81. Wardas J., Pietraszek M., Wolfarth S. and Ossowska K. (2003) The role of metabotropic glutamate receptors in regulation of striatal pro-enkephalin expression: implications for the therapy of Parkinson's disease. Neuroscience 122, 747-756.
82. Westin J. E., Andersson M., Lundblad M. and Cenci M. A. (2001) Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease. Eur. J. Neurosci. 14, 1171-1176.
83. Westin J. E., Vercammen L., Strome E., Konradi C. and Cenci M. A. (2007) Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry; in press.
84. Windels F., Carcenac C., Poupard A. and Savasta M. (2005) Pallidal origin of GABA release within the substantia nigra pars reticulata during high-frequency stimulation of the subthalamic nucleus. J. Neurosci. 25, 5079-5086.
85. Winkler C., Kirik D., Bjorklund A. and Cenci M. A. (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 10, 165-186.